Investigational drug · Phase 2
EL219
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Invasive Mould Infection.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "EL219"
First trial start
2026
Feb 13, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "EL219", any sponsor or status.
Conditions studied
As listed on its trial records.
- Invasive Mould Infection
Approved drugs for the same conditions: Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "EL219" as an intervention, largest first.
- Phase 2 EL219 Versus Liposomal Amphotericin B or Voriconazole for Early Antifungal TherapyRecruiting
Elion Therapeutics, Inc.Industry
NCT07215273 · 60 participants (planned) · Start Feb 13, 2026 · Primary completion Dec 2026
Drug: EL219; Active Comparator- IV Antifungal (LAmB or voriconazole) · For: Invasive Mould Infection
Sites: Birmingham, Alabama; Sacramento, California; Augusta, Georgia · 30 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Erratum for Wiederhold et al., "The next-generation polyene EL219 is efficacious in an experimental model of central nervous system coccidioidomycosis caused by Coccidioides immitis".
Wiederhold NP, Najvar LK, Jaramillo R, et al. · Antimicrob Agents Chemother 2026
- The next-generation polyene EL219 is efficacious in an experimental model of central nervous system coccidioidomycosis caused by Coccidioides immitis.
Wiederhold NP, Najvar LK, Jaramillo R, et al. · Antimicrob Agents Chemother 2026
- Efficacy assessments of EL219, a next-generation polyene antifungal, in immunosuppressed mice infected with drug-sensitive and drug-resistant Aspergillus isolates.
Youssef EG, Gebremariam T, Gu Y, et al. · Antimicrob Agents Chemother 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.